IRIS - Res&Arch Institutional Research Information System - Research & Archive

PACIOTTI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.077
EU - Europa 961
AS - Asia 318
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 2.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.075
IT - Italia 268
IE - Irlanda 250
FR - Francia 108
HK - Hong Kong 100
CN - Cina 78
UA - Ucraina 76
VN - Vietnam 67
SG - Singapore 63
RO - Romania 49
SE - Svezia 44
FI - Finlandia 38
DE - Germania 36
RU - Federazione Russa 36
BE - Belgio 13
GB - Regno Unito 11
TR - Turchia 8
CH - Svizzera 7
GR - Grecia 6
AT - Austria 5
CZ - Repubblica Ceca 5
NL - Olanda 5
PL - Polonia 3
MX - Messico 2
AU - Australia 1
BR - Brasile 1
EU - Europa 1
JP - Giappone 1
NO - Norvegia 1
UZ - Uzbekistan 1
Totale 2.359
Salva come PNG Salva come JPEG
Città #
Chandler 276
Dublin 250
Perugia 156
San Mateo 104
Hong Kong 100
Ann Arbor 68
Dong Ket 67
Altamura 59
Beijing 54
Bucharest 49
Wilmington 46
Medford 44
Princeton 44
Jacksonville 38
Lawrence 38
Singapore 38
Ashburn 28
Des Moines 27
Andover 26
Redmond 21
Helsinki 15
Brussels 13
Saint Petersburg 13
Boardman 10
Los Angeles 10
Redwood City 10
Norwalk 8
Houston 7
Izmir 7
San Paolo di Civitate 7
Seattle 6
Woodbridge 6
Fairfield 5
Falls Church 5
Chicago 4
Milan 4
Cambridge 3
Den Haag 3
Florence 3
Moscow 3
Assisi 2
Brno 2
Lappeenranta 2
Lausanne 2
Olomouc 2
Rome 2
Spoleto 2
Vienna 2
Aksaray 1
Amsterdam 1
Bergen 1
Changsha 1
Ergolding 1
Esslingen am Neckar 1
Frankfurt Am Main 1
Gunzenhausen 1
Irakleio 1
Irvine 1
Melbourne 1
Mexico City 1
Monmouth Junction 1
Munich 1
Napoli 1
New York 1
Oleggio 1
Parabiago 1
Queens 1
Radeberg 1
Shanghai 1
Simi Valley 1
Tappahannock 1
Teresina 1
Tokyo 1
Wageningen 1
Zero Branco 1
Totale 1.718
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 113
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration 104
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients 89
Accumulation of free oligosaccharides and tissue damage in cytosolic alpha-mannosidase (Man2c1)-deficient mice. 88
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease 75
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies 74
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies 70
Lysosomal alpha-mannosidase and alpha-mannosidosis 67
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease 67
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis 64
Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. 63
null 63
Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies 62
di-N-acetylchitobiase-deficient mice accumulate Man2GlcNAc2 and Man3GlcNAc2 61
Lysosomal enzymes in Parkinson's disease 61
Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids 60
Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. 59
Identification of two novel beta-mannosidosis-associated sequence variants: biochemical analysis of beta mannosidase (MANBA) missense mutations. 58
Free oligosaccharides accumulation and tissue damages in Ma2c1 deficient mice 58
Lysosomal di-N-acetylchitobiase-deficient mouse tissues accumulate Man2GlcNAc2 and Man3GlcNAc2 54
The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction 54
Generation of a chitobiase knock out mouse model 53
Are we ready for detecting α-synuclein prone to aggregation in patients? The case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as diagnostic tools 52
Novel CSF biomarkers to discriminate FTLD and its pathological subtypes 51
Molecular cloning and structural organization of the gene encoding the mouse lysosomal di-N-acetylchitobiase (ctbs) 48
Biochemical analysis of missense mutations in beta-mannosidosis 48
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 48
Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis 47
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients 47
Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links 45
Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma 44
Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid. 43
Next generation sequencing applications in agro biotechnology 43
Fingerprinting Alzheimer's Disease by 1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid 43
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 43
Emerging therapies and therapeutic concepts for lysosomal storage diseases 40
Origin of α-mannosidase activity in CSF 39
Parkinson's and Lewy body dementia CSF biomarkers 38
Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease 36
Dopamine-dependent early synaptic and motor dysfunctions induced by a-synuclein in the nigrostriatal circuit 36
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease 34
Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease 30
Lysosomal enzymes in PD: further evidence is needed. 30
Interlaboratory proficiency processing scheme in CSF aliquoting: Implementation and assessment based on biomarkers of Alzheimer's disease 30
First pilot newborn screening for our lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene 29
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 22
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 12
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 12
Totale 2.507
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.547
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020275 22 11 18 2 27 2 46 20 15 46 26 40
2020/2021341 7 18 2 20 99 9 23 11 33 16 21 82
2021/2022504 16 78 7 11 7 19 6 107 37 51 74 91
2022/2023867 51 162 15 75 66 97 0 34 324 1 31 11
2023/2024303 27 28 25 6 2 1 75 14 20 14 47 44
2024/20251 1 0 0 0 0 0 0 0 0 0 0 0
Totale 2.507